Autoimmune
Novartis antibody ianalumab clinches another Phase 3 win in rare blood disease (ITP)
Novartis; ianalumab; VAY736; primary immune thrombocytopenia; ITP; rare disease; Phase 3; time to treatment failure; safe platelet levels; eltrombopag; autoimmune; B-cell depletion; BAFF-R inhibition; Sjögren’s disease; regulatory submissions
Odyssey Therapeutics Abandons IPO Plans in Latest Sign of Tough Environment for Biotech Listings
Odyssey Therapeutics; IPO; biotech; withdrawal; SEC; market turbulence; autoimmune
Sanofi pens $1.8B research deal for 2 bispecific antibodies aimed at autoimmune, immunology
Antibodies, Bispecific, Autoimmune, Inflammatory Bowel Diseases, sanofi, Earendil Labs, Immunology, Collaboration, development aspects
Exclusive: Merida Biosciences gets $121M to treat autoimmune and allergy diseases at their roots
Autoimmune, Autoimmune Diseases, Precision – temporal